Correlates of Risk for Disinhibited Behaviors in the Million Veteran Program Cohort

Peter B. Barr *[1-4], Tim B. Bigdeli *[1-4], Jacquelyn L. Meyers [1-4],
Roseann E. Peterson [1-3], Sandra Sanchez-Roige [5,6], Travis T. Mallard [7,8],
Danielle M. Dick [9,10], K. Paige Harden [11,12], Anna Wilkinson [13,14,15],
David P. Graham [13,16], David A. Nielsen [13,16], Alan Swann [13,16],
Rachele K. Lipsky [13,16], Thomas Kosten [13,16], Mihaela Aslan [17,18],
Cooperative Studies Program (CSP) #572, Million Veteran Program,
Philip D. Harvey [†19,20], Nathan A. Kimbrel [†21-23], and Jean C. Beckham [†21-23]

1. VA New York Harbor Healthcare System, Brooklyn, NY
2. Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University, Brooklyn, NY
3. Institute for Genomics in Health (IGH), SUNY Downstate Health Sciences University, Brooklyn, NY
4. Department of Epidemiology and Biostatistics, School of Public Health, SUNY Downstate Health Sciences University, Brooklyn, NY
5. Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
6. Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
7. Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
8. Department of Psychiatry, Harvard Medical School, Boston, MA, USA
9. Department of Psychiatry, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ
10. Rutgers Addiction Research Center, Rutgers University, Piscataway, NJ
11. Department of Psychology, University of Texas at Austin, Austin, TX
12. Population Research Center, University of Texas at Austin, Austin, TX
13. Michael E. DeBakey VA Medical Center, Houston, TX
14. UTHealth Houston School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX
15. Michael and Susan Dell Center for Healthy Living, The University of Texas Health Science Center at Houston, Houston, TX
16. Department of Psychiatry, Neuroscience, Pharmacology, and Immunology and Rheumatology, Baylor College of Medicine, Houston, TX
17. Clinical Epidemiology Research Center (CERC), VA Connecticut Healthcare System, West Haven, CT
18. Yale University School of Medicine, New Haven, CT
19. Research Service, Bruce W. Carter Miami Veterans Affairs (VA) Medical Center, Miami, FL
20. University of Miami Miller School of Medicine, Miami, FL
21. Durham VA Health Care System, Durham, NC
22. VA Mid-Atlantic Mental Illness Research, Education and Clinical Center, Durham, NC
23. Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC

* These authors contributed equally to this work; † These authors jointly supervised this work

Corresponding author: Peter B. Barr
450 Clarkson Ave, MSC 1203, Brooklyn, NY 11203
e-mail: peter.barr@downstate.edu.
Running Header: Correlates of Externalizing Risk in Veterans
Word count abstract: 267; Word count text body: 3,550; Figures and Tables: 3 Figures

ABSTRACT

Many psychiatric outcomes are thought to share a common etiological pathway reflecting behavioral disinhibition, generally referred to as externalizing disorders (EXT). Recent genome-wide association studies (GWAS) have demonstrated the importance of EXT for aspects of veterans' health, such as suicide-related behaviors, substance use disorders, and other medical conditions. To better understand how genetic risk for EXT is related to veterans' health, we conducted a series of phenome-wide association studies (PheWAS) of polygenic scores (PGS) for EXT, and comorbid psychopathology (depression, schizophrenia, suicide attempt) in an ancestrally diverse cohort of U.S. veterans (Total *N* = 560,824), using diagnostic codes from electronic health records. First, to identify phenotypes associated with the EXT PGS, we conducted ancestry-specific PheWAS in the European, African, and Admixed American ancestries (separately). Second, to determine if associations were driven by risk for other comorbid psychiatric conditions, we performed a conditional PheWAS of the significant associations from the main PheWAS, covarying for PGS related to depression, schizophrenia, and suicide attempt (European ancestries only). Lastly, to adjust for unmeasured confounders we performed a within-family PheWAS of the significant associations from the main PheWAS in full-siblings identified in MVP (N = 12,127, European ancestries only). EXT PGS was associated with outcomes across all bodily systems, independent of risk for depression, schizophrenia, or suicide attempt. Within-family analyses uncovered robust associations between EXT and consequences of substance use disorders, including chronic liver disease, chronic airway obstruction, and viral hepatitis C. These results demonstrate a shared polygenic basis of EXT across populations of diverse ancestries and highlight the negative consequences of EXT for health and functioning in the US veteran population.

INTRODUCTION

Psychiatric disorders have far-reaching consequences for affected individuals, their families, communities, and the broader society [1–4]. Many of these disorders are strongly co-morbid and share, at least in part, a common etiology [5]. Disorders related to behavioral disinhibition, such as substance use disorders (SUD), conduct disorder, and antisocial personality disorder, have been labeled as externalizing disorders [6,7]. Twin and family studies suggest that the common liability towards externalizing disorders is highly heritable (~80%) [8–10]. Recent multivariate genome wide association studies (GWAS) have found robust evidence for a latent genomic factor for externalizing disorders [11,12], composed of input GWAS related to substance use disorders, risky sexual behaviors, personality characteristics, and neurodevelopmental disorders. Importantly, genetic liability for externalizing disorders overlaps with other phenotypes of public health relevance, such as suicidal thoughts and behaviors [11,13–15], SUDs [11,16–18], and a range of other medical conditions (e.g., ischemic heart disease, liver disease, viral hepatitis) [11]. The widespread impact of risk for externalizing disorders makes it a potential target for early intervention and prevention.

The proliferation of large-scale biobanks – such as All of Us [19], the UK Biobank [20], FinnGen [21], and Biobank Japan [22] – linking individual-level genomic data with electronic health records (EHRs) presents opportunities to further explore the relationships between genetic liability for a given disorder (typically in the form of polygenic scores, or PGS), and a wide range of clinical phenotypes. This hypothesis free approach, referred to as a phenome-wide association study (PheWAS) [23], can aid in identifying novel trait associations and understanding pleiotropic effects. Recent PheWAS using PGS for other psychiatric problems (e.g., schizophrenia, bipolar disorder, and depression) have identified widespread associations between PGS and a host of psychiatric and other medical diagnoses [24,25].

In the current analysis, we applied a PheWAS of a PGS derived from a multivariate GWAS of externalizing disorders/problems (EXT) [11] to the EHRs of the Department of Veterans Affairs Million Veterans Program Cohort (MVP) [26]. A previous PheWAS of the EXT PGS in the Vanderbilt University Medical Center Biobank (BioVU) [27] identified over 250 associations with EHR derived medical conditions

[11], but was limited to individuals of European ancestries. We extend the PheWAS of the EXT PGS all veterans of European, African, and Hispanic/Latin American ancestries. We further compared results from our primary PheWAS of EXT to analogously derived results for PGSs of schizophrenia (SCZ) [28], depression (DEP) [29], and suicide attempt [13], including joint modeling of these PGS. Finally, we attempted to replicate the findings from the primary PheWAS in a holdout sample of related veterans (full siblings). Genetic differences between siblings are random; therefore, within sibship associations between the EXT PGS and health outcomes cannot be attributed to between-family sources of confounding, such as environmental exposures that are correlated with population stratification.

METHODS

The Million Veterans Program Cohort (MVP)

Launched in 2010, MVP is a landmark endeavor that links genomic laboratory testing, survey-based self-report data, and EHRs, with the goal of creating a “mega-biobank” and evidence base for precision medicine initiatives [26]. The 850,000 enrolled participants reflect the population that utilizes the Veterans Health Administration (VHA), with over-representation of older and male individuals, as well as higher rates of multiple morbidities and chronic conditions related to externalizing compared to the general population [30,31]. Participants are active users of the VHA healthcare system and were recruited through invitational mailings or by MVP staff while receiving clinical care. Informed consent and authorization per the Health Insurance Portability and Accountability Act (HIPPA) were the only other inclusion criteria. Once enrolled, participants EHR data are linked, including diagnostic codes, routine laboratory results, and medications. The current analysis uses Release 4 of MVP data, as collection is ongoing. The present analyses were approved by the VA Central Institutional Review Board (IRB), and all participants provided written informed consent.

Genotyping

MVP participants were genotyped on the MVP 1.0 Axiom array [32]. Genetic ancestries of participants were classified using the HARE (harmonized ancestry and race-ethnicity) method [33], which

harmonizes the closest ancestral population with self-identified race and ethnicity. Genotypic data were imputed to the Trans-Omics for Precision Medicine (TOPMed) reference panel [34], which specifically improves imputation quality in non-European and admixed ancestries [35]. As of Release 4, there are 467,101 veterans of predominantly European ancestries (EUR), 124,717 veterans of predominantly African ancestries (AFR), 52,416 veterans of predominantly Hispanic/Latin American ancestries (HIS), and 8,362 veterans of predominantly Asian ancestries (ASN) with available genotypic and electronic health record data. In the current analysis, we included data from the EUR, AFR, and HIS groups, as these had sufficient statistical power for the number of associations tested. Within each of these HARE categories, we restricted analyses to unrelated individuals, excluding all those who were second-degree relatives or closer (KING coefficient ≤ 0.177). Within each ancestry group, we limited to those whose primary self-identified race-ethnicity matched their HARE classification, so as to not introduce potential confounding driven by well-characterized health disparities [36,37].

Electronic health records (EHRs)

Our main outcomes for the analyses were phecodes, which are clusters of ICD-9/10-CM codes in the EHR [38,39] and have been validated previously [40,41]. We considered individuals as having a diagnosis for any given phecode if there were two or more occurrences of that phecode in their EHR. Prior analyses have shown that 2 or more phecodes as a good predictor diagnosis [24,25]. Phecodes are grouped into 17 categories: infectious diseases, neoplasms, endocrine/metabolic, hematopoietic, mental disorders, neurological, sense organs, circulatory system, respiratory, digestive, genitourinary, pregnancy complications, dermatologic, musculoskeletal, congenital anomalies, symptoms, and injuries & poisonings. We excluded phecodes for which there were fewer than 100 cases with the diagnosis. In total, there were 1,652 phecodes, 1,436 phecodes, and 1,125 phecodes with $N > 100$ diagnoses available for EUR, AFR, and HIS veterans, respectively.

Polygenic scores (PGS)

We estimated PGSs derived from four large-scale GWASs: externalizing problems (EXT, $N_{effective}$= 1,492,085) [11], depression (DEP, $N_{effective}$ = 449,856) [29], schizophrenia (SCZ, $N_{effective}$ = 117,498) [28], and suicide attempt (SUI, $N_{effective}$ = 91,230) [13]. We focus on these three PGS in addition to the EXT PGS because these phenotypes are genetically correlated with EXT [11] and could confound associations between EXT and phenotypes of interest (e.g., SUDs, suicidal behaviors, other psychiatric disorders).

In EUR ancestries, we created PGS using PRS-CS [42], a Bayesian regression and continuous shrinkage method that uses an external reference panel (e.g., 1000 Genomes Phase III European subsample) to estimate the posterior effect sizes for each SNP in a given set of GWAS summary statistics. In the AFR and HIS ancestries, we used a different approach. PGS accuracy decays continuously as target samples differ in ancestry from the discovery GWAS, even within relatively homogenous genetic clusters [43] and we lacked ancestry-matched GWAS for EXT to use methods that boost power of PGS in underpowered samples, such as PRS-CSx [44]. Therefore, in the AFR and HIS ancestries, we created EXT PGS using the 579 loci reported in the externalizing GWAS, as using genome wide significant variants is more robust to population stratification [45]. We standardized all PGS to Z-scores.

Analytic plan

We first conducted a phenome-wide association study (PheWAS) to examine the association between the EXT PGS and 1,652 phecodes within EUR ancestries, using logistic regression and covarying for age, sex, and twenty ancestry principal components (PCs). Next, we attempted to replicate any phenome-wide significant associations within AFR and HIS ancestries. Third, we performed a conditional multi-PGS PheWAS, including all PGS in the same model, to test whether associations between EXT remained after conditioning on the DEP, SCZ, and SUI PGSs. Lastly, to control for additional confounders, we used a subset of full siblings (N = 12,127) identified through genetic data, to test for associations between EXT and phecodes within-family. For within-family models, we used a linear

probability model as opposed to logistic regression, as the fixed effects logistic regression can provide biased estimates when the number of observations per group is relatively small [46].

Finally, we also performed a series of sensitivity analyses, co-varying for total comorbidity burden, created by tabulating the number of unique phecode terms for which an individual met criteria for the 600 top parent codes, and then transforming this count using an inverse normal transformation [25]. We applied a multiple testing correction for 1,652 tests across the 4 PGS included in the analyses for EUR ancestries ($p < .05/6608 = p < 7.57\text{x}10^{-4}$). We used a less conservative approach to multiple testing in the AFR and HIS ancestries given the expected reduction in predictive power of PGS, applying a false discovery rate (FDR) [47] of 5%.

RESULTS

Main PheWAS of EXT PGS

Of the 467,101 veterans of broadly European ancestries (EUR), we filtered down to a sample of 438,384 unrelated individuals. After removing those with any missing information, those without available EHR data, and retaining those whose primary identity was Non-Hispanic White, *N* = 406,254 participants were available for the initial PheWAS in EUR (mean age = 69.8, SD = 14.1; 92.8% male). We performed a similar process for veterans of African (AFR, *N* = 112,390, mean age = 63.5, SD = 12.6; 86.3% male) and Hispanic/Latin American (HIS, *N* = 42,179, mean age = 60.5, SD = 16.2; 90.4% male) ancestries. Supplemental Table 1 presents all demographic statistics.

Figure 1, Panel A presents selected results from the main PheWAS within EUR. Of the 1,652 total phecodes we tested, 619 (37.5%) were significantly associated with EXT PGS after correcting for multiple testing. We observed significant associations for EXT PGS across all virtually all bodily systems, with the strongest specific positive associations being between EXT PGS and viral hepatitis C (OR = 1.49; 95% CI = 1.46, 1.51), substance addiction and disorders (OR = 1.39; 95% CI = 1.37, 1.40), embolism/thrombosis of the abdominal aorta (OR = 1.36; 95% CI = 1.22, 1.51), tobacco use disorders (OR = 1.35; 95% CI = 1.34, 1.36), and cancer of the mouth (OR = 1.33; 95% CI = 1.17, 1.50). We also

observed robust negative associations with autism (OR = 0.76; 95% CI = 0.68, 0.86), intestinal infection (OR = 0.85; 95% CI = 0.80, 0.90), disorders of bilirubin excretion (OR = 0.90; 95% CI = 0.86. 0.94), and prostate cancer (OR = 0.97; 95% CI = 0.95, 0.98). The full results are in Supplemental Table 2.

Panel B presents variation in effect sizes based on ORs across phecode categories. Overall, there is a shift in median effect size above one, with the exception of pregnancy complications, which is not unexpected given the predominantly male composition of this study sample. Median effect sizes ranged from 0.98 for pregnancy complications to 1.12 for respiratory related phecodes. While there was variation in effect sizes across groupings of phecodes, the largest associations, on average, were for phecodes related to respiratory issues, mental disorders, injuries & poisonings, and infectious diseases (median ORs = 1.10 – 1.12).

To examine whether EXT was associated with any of the 619 outcomes due to the increased number of comorbidities associated with higher levels of externalizing, we ran the PheWAS including a covariate for total comorbidity burden in veterans of European ancestries. Of the 619 significant associations, 216 remained associated with EXT after adjusting for total comorbidity burden, with the top associations remaining those for viral hepatitis, substance use disorders, and complications from smoking (full results in Supplemental Table 3).

Multi-Ancestry Verification of EXT PGS

Lastly, we examined whether EXT PGS associations that were significant in the main EUR analyses were comparable in the AFR and HIS MVP participants. Among the 619 significant associations in veterans of EUR ancestries, 614 were available (N_{DX} >100) and 73 (11.9%) were significant in veterans of AFR ancestries, 584 were available and 26 (4.5%) were significant in veterans of HIS ancestries after correcting for multiple testing. A subset of these replicated associations are presented in Figure 2. Associations that replicated were related to some of the strongest associations in the EUR analyses, including SUDs (alcohol, tobacco, and other substances), viral hepatitis, and problems related to the respiratory system (e.g., cancer, chronic airway obstruction, and respiratory failure). As expected, while

these associations were significant, there was a large attenuation in effect sizes, consistent with using PGS derived from ancestries that differ from the target sample [44,45] (full results in Supplemental Table 3).

Joint PheWAS of EXT, DEP, SCZ, and SUI PGSs

Next, we investigated whether the 619 phecodes associated with EXT PGS remained associated in models after conditioning on the DEP, SCZ, and SUI PGS. First, we next compared the results from PheWAS of each PGS, individually. Figure 2A presents the breakdown of phenome significant associations across the four PGS. Across all the PGSs (6,608 tests), 779 (11.78%) associations had p-values below the Bonferroni corrected *p*-value ($p < 7.58 \times 10^{-4}$). The majority of these associations (56.1 %, N = 437) involved three of the four PGSs, and over 70% (N = 561) involved two or more of the PGSs, suggesting that many of these PGS may be indexing a common source of risk, though the PGSs were only weakly correlated ($r \sim 0.2 - 0.3$, full results in Supplemental Table 5).

Of the 619 associations with EXT, 494 (79.8%) remained associated after conditioning on the other PGS and correcting for multiple testing ($p < .05/619 = p < 8.08 \times 10^{-5}$). Effect sizes ranged from 1.02 for overweight/obesity (phecode = 278; 95% CI = 1.01, 1.03) to 1.44 for viral hepatitis C (phecode 070.3; 95% CI = 1.42, 1.47) for traits positively related to the EXT PGS. Effect sizes for negative associations ranged from 0.74 for a diagnosis of autism (phecode = 313.3; 95% CI = 0.65, 0.84) to 0.97 for melanomas of the skin (phecode = 172.1; 95% CI = 0.96, 0.99). Associations that were no longer significant spanned all bodily systems, and included schizophrenia, rheumatoid arthritis, and chronic sinusitis, among many others. The median OR for the EXT PGS dropped from 1.10 in the marginal associations with these phecodes to 1.08 after conditioning on the other PGSs. Figure 2B presents a subset of the larger associations (OR >1.15, full results in Supplementary Table 6). While there was attenuation in effect sizes, EXT remained associated with the various phecodes independent of risk for DEP, SCZ, or SUI.

Within-family replication of Main PheWAS Results

Finally, we investigated the 494 phecodes that remained significantly associated with EXT in the conditional PheWAS using a sample of full siblings from the broader MVP (*N* = 12,127). Of these 494

phecodes, 439 had available information in the subset of related veterans. Within these remaining 439 associations, 77 were marginally significant ($p < .05$) but only 13 of these associations remained after correcting for multiple testing using a false discovery rate (FDR) of 5%. Though many of the SUD phecodes were strongly associated in the main PheWAS and marginally significant in the within-family associations, only the tobacco use disorders association survived corrections for multiple testing ($\beta_{within} = 0.049$, $p < 1.28 \times 10^{-7}$, see Supplemental Table 7 for full results).

Interestingly, the associations that remained significant within-family were overwhelmingly related to downstream consequences of various forms of substance use, including viral hepatitis C, chronic liver disease and cirrhosis, chronic airway obstruction, and ischemic heart disease. Figure 3 shows the relative effect sizes from the linear probability models with (ordinary least squares, or OLS) and without (within-family) family fixed-effects. For some of the associations we see a marked decrease in effect size. Therefore, a non-trivial portion of the association between the EXT PGS and these phenotypes may be due to some type of confounding. However, for viral hepatitis C, tobacco use disorder, and chronic airway obstruction, there is little or no attenuation, and these estimates could reflect some type of causal pathway between underlying risk and disease state.

DISCUSSION

Problems related to behavioral disinhibition, commonly referred to as externalizing, can have far reaching health consequences. We and others have shown that risk for EXT disorders overlaps with a variety of key public health outcomes at both the genetic and phenotypic level [11,13–18,48]. In the current analysis, we leveraged these recent, novel insights into the underlying biology of EXT, extended analyses to multiple ancestries, and evaluated their correlates and consequences in the largest integrated healthcare system in the US.

Results from the main PheWAS replicated the diversity of bodily systems that were associated with risk for externalizing disorders [11]. As expected, some of the strongest associations were in the phecode domain of *mental disorders*. Specifically, substance use disorders (alcohol, tobacco, and other

substances) and suicidal thoughts and behaviors (suicide ideation, attempt, and self-harm) were among the strongest associations, though other psychiatric problems, including conduct disorder, personality disorders, and mood disorders were also associated. Some components, specifically problematic alcohol use and smoking, contributed to the multivariate GWAS used for creating the EXT PGS [11], but analyses in the original EXT paper showed that the latent factor was not driven by any single indicator, so it is unlikely that associations are driven any indicator-outcome similarity. Interestingly, EXT remained associated with suicide-related phecodes even when conditioning on the suicide PGS, suggesting that the association between externalizing and suicidal behaviors is independent of risk for the other forms of psychiatric problems (e.g., depression), supporting the role of impulsivity in suicide risk [49]. Overall, these results point to a robust pathway between risk for externalizing disorders and numerous medical conditions that replicated across ancestry, was not explained by risk for other common forms of psychiatric problems and could not be fully explained by documented comorbidities.

The EXT PGS was associated with *reduced* risk for 6 phecodes: prostate cancer, melanoma, disorders of bilirubin excretion, autism, celiac disease, and flat foot. While associations may reflect a true reduced risk, the negative associations may also reflect our use of lifetime diagnosis. Because several of these diseases are strongly age-graded, supposedly protective associations may reflect bias due to mortality selection. Future work can leverage the longitudinal EHR data in MVP to characterize the association between and early mortality to determine whether there is any true protective effect.

The expansive MVP cohort allowed us the opportunity to explore the possibility of confounding influences via a *novel* approach: leveraging an appreciable number of full-siblings that comprise less than 2% of the overall cohort. The within-family analyses presented an additional test of whether EXT is simply a correlate or potentially causally related to various phecodes. In the holdout sample of full siblings, only a portion of the associations (13/439, 3.0%) remained associated after correcting for multiple testing. While suicide ideation, attempt and self-harm was one of the stronger associations in the PheWAS, it did not replicate on a within-family basis. This may have been due to the relatively few cases of suicidal ideation, attempt or self-harm in the EHR of the smaller within-family sample (n = 205, 1.7%). In terms of

SUDs, only tobacco use disorders remained significant after multiple testing correction, though alcohol related disorders (phecode 317) was marginally significant. There was insufficient within-family variation to include substance and addiction disorders (phecode 316) in the within-family models. Moreover, many of the associations that replicated within-family were likely *consequences* of SUDs. These included chronic airway obstruction (smoking-related), chronic liver disease and cirrhosis (alcohol-related), and viral hepatitis C (intravenous drug use related). The within-family associations point to the potential causal impact of risk for externalizing on these medical conditions, likely mediated through SUDs. It is important to note that even though within-family associations are robust to confounding, they can be biased in the presence of genetic nurture and sibling effects [50].

Our analysis has several important limitations. First, although we included large samples of multiple ancestries, PGS were derived from a GWAS of primarily European ancestries. Consistent with recent observations of other PGS in MVP [25], the EXT PGS was associated with many of the traits within the AFR and HIS samples, but the effect sizes were highly attenuated. Large-scale discovery GWAS in diverse cohorts are vital to ensuring that PGS perform as well in these groups and that any benefit of precision medicine is shared equitably across the population [51]. Second, results from this sample may not be generalizable to the broader U.S. population. While generally representative of the VA, MVP is still a selected subset comprising primarily male individuals. Additional work is needed to ensure that the study results generalize beyond the VA. Third, we did not examine PGS in conjunction with social and environmental factors. Both polygenic and environmental risk factors are important for understanding key outcomes in veterans' health, including substance use disorders [48], major depressive disorder [52], and other mental health problems [53]. Many veterans are at risk for adverse environmental experiences due to poverty, minority status, and physical and psychiatric challenges [54]. Future work should endeavor to move beyond the focus on genetic or environmental risk in isolation and towards integrated approaches.

Downstream consequences of risk for externalizing disorders present a serious public health concern. A predisposition towards greater levels of externalizing is associated with increased risk of substance use disorders, suicide related behaviors, and other chronic medical conditions. Our analysis

demonstrated that externalizing risk is equally important among the US veteran population who receive their healthcare within the VA system. Intervention and prevention efforts that identify ways to target and monitor the behavioral manifestations of externalizing risk (e.g., improving impulse control) could substantially improve morbidity and mortality outcomes.

ACKNOWLEDGEMENTS

The views expressed in this article are those of the authors, and do not necessarily reflect the position or policy of the Department of Veterans Affairs (VA). The Million Veteran Program (MVP) is funded by grant #MVP000 from the VA Office of Research and Development (ORD). This work was also funded by grant #1I01CX001729 from the Clinical Services Research & Development (CSRD) Service of VA ORD to Drs. Beckham and Kimbrel, by the MVP CHAMPION program, which is a collaboration between the VA and the Department of Energy (DoE), and by a CSRD Senior Research Scientist award (IK6BX003777) to Dr. Beckham. Drs. Barr, Bigdeli, Aslan, and Harvey are supported by VA Cooperative Studies Program (CSP) #572. Drs. Peterson, Bigdeli, and Meyers are supported by the National Institute of Mental Health (R01MH125938). Dr. Peterson is also supported by the National Institute on Alcohol Abuse and Alcoholism (P50AA022537) and the Brain Behavior Research Foundation NARSAD grant 28632 PS Fund. Dr. Sanchez-Roige was supported by funds from the California Tobacco-Related Disease Research Program (TRDRP; Grant Number T29KT0526 and T32IR5226) and the National Institute on Drug Abuse (DP1DA054394). Dr. Mallard is supported by funds from NIH T32HG010464. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

We would also like to thank The Externalizing Consortium for sharing the GWAS summary statistics of externalizing. The Externalizing Consortium: Principal Investigators: Danielle M. Dick, Philipp Koellinger, K. Paige Harden, Abraham A. Palmer. Lead Analysts: Richard Karlsson Linnér, Travis T. Mallard, Peter B. Barr, Sandra Sanchez-Roige. Significant Contributors: Irwin D. Waldman. The Externalizing Consortium has been supported by the National Institute on Alcohol Abuse and Alcoholism (R01AA015416 -administrative supplement), and the National Institute on Drug Abuse (R01DA050721). Additional funding for investigator effort has been provided by K02AA018755, U10AA008401, P50AA022537, as well as a European Research Council Consolidator Grant (647648 EdGe to Koellinger). The content is solely the responsibility of the authors and does not necessarily represent the

official views of the above funding bodies. The Externalizing Consortium would like to thank the following groups for making the research possible: 23andMe, Add Health, Vanderbilt University Medical Center's BioVU, Collaborative Study on the Genetics of Alcoholism (COGA), the Psychiatric Genomics Consortium's Substance Use Disorders working group, UK10K Consortium, UK Biobank, and Philadelphia Neurodevelopmental Cohort.

We would like to thank the U.S. Veteran participants in MVP for their service, and for their time, samples, and continued participation in VA research. Without them, this work would not be possible.

REFERENCES

1. Ferrari, A. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Psychiatry* **9**, 137–150 (2022).
2. Murray, C. J. L. *et al.* The state of US health, 1990-2016: Burden of diseases, injuries, and risk factors among US states. *JAMA - Journal of the American Medical Association* **319**, 1444–1472 (2018).
3. Reitsma, M. B. *et al.* Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. *The Lancet* **389**, 1885–1906 (2017).
4. Degenhardt, L. *et al.* The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Psychiatry* **5**, 987–1012 (2018).
5. Anttila, V. *et al.* Analysis of shared heritability in common disorders of the brain. *Science (1979)* **360**, eaap8757 (2018).
6. Achenbach, T. M. The classification of children's psychiatric symptoms: a factor-analytic study. *Psychol Monogr* **80**, 1–37 (1966).
7. Kotov, R. *et al.* The Hierarchical Taxonomy of Psychopathology (HiTOP) in psychiatric practice and research. *Psychol Med* **52**, 1666–1678 (2022).
8. Hicks, B. M., Krueger, R. F., Iacono, W. G., McGue, M. & Patrick, C. J. Family transmission and heritability of externalizing disorders: A Twin-Family Study. *Arch Gen Psychiatry* **61**, 922–928 (2004).
9. Krueger, R. F. *et al.* Etiological connections among substance dependence, antisocial behavior and personality: Modeling the externalizing spectrum. *J Abnorm Psychol* **111**, 411–424 (2002).
10. Barr, P. B. & Dick, D. M. The Genetics of Externalizing Problems. *Curr Top Behav Neurosci* **47**, 93–112 (2020).

11. Karlsson Linnér, R. *et al.* Multivariate analysis of 1.5 million people identifies genetic associations with traits related to self-regulation and addiction. *Nat Neurosci* 1–10 (2021) doi:10.1038/s41593-021-00908-3.

12. Baselmans, B. *et al.* The Genetic and Neural Substrates of Externalizing Behavior. *Biological Psychiatry Global Open Science* **2**, 389–399 (2022).

13. Mullins, N. *et al.* Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. *Biol Psychiatry* **91**, 313–327 (2022).

14. Johnson, E. C. *et al.* Associations between Suicidal Thoughts and Behaviors and Genetic Liability for Cognitive Performance, Depression, and Risk-Taking in a High-Risk Sample. *Complex Psychiatry* **7**, 34–44 (2021).

15. Bigdeli, T. *et al.* Correlates of suicidal behaviors and genetic risk among United States veterans with schizophrenia or bipolar I disorder. *medRxiv* 2023.03.06.23286866 (2023) doi:10.1101/2023.03.06.23286866.

16. Kranzler, H. R. *et al.* Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. *Nat Commun* **10**, 1499 (2019).

17. Demontis, D. *et al.* Genome-wide association study implicates CHRNA2 in cannabis use disorder. *Nat Neurosci* **22**, 1066–1074 (2019).

18. Deak, J. D. *et al.* Alcohol and nicotine polygenic scores are associated with the development of alcohol and nicotine use problems from adolescence to young adulthood. *Addiction* **117**, 1117–1127 (2022).

19. The All of Us Research Program Investigators. The “All of Us” Research Program. *New England Journal of Medicine* **381**, 668–676 (2019).

20. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).

21. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature* **613**, 508–518 (2023).

22. Nagai, A. *et al.* Overview of the BioBank Japan Project: Study design and profile. *J Epidemiol* **27**, S2–S8 (2017).

23. Denny, J. C. *et al.* PheWAS: Demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. *Bioinformatics* **26**, 1205–1210 (2010).

24. Zheutlin, A. B. *et al.* Penetrance and pleiotropy of polygenic risk scores for schizophrenia in 106,160 patients across four health care systems. *American Journal of Psychiatry* **176**, 846–855 (2019).

25. Bigdeli, T. B. *et al.* Penetrance and Pleiotropy of Polygenic Risk Scores for Schizophrenia, Bipolar Disorder, and Depression among Adults in the US Veterans Affairs Health Care System. *JAMA Psychiatry* **79**, 1092–1101 (2022).

26. Gaziano, J. M. *et al.* Million Veteran Program: A mega-biobank to study genetic influences on health and disease. *J Clin Epidemiol* **70**, 214–223 (2016).

27. Davis, L. Psychiatric Genomics, Phenomics, and Ethics Research In A 270,000-Person Biobank (BioVU). *European Neuropsychopharmacology* **29**, S739–S740 (2019).

28. Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature* **604**, 502–508 (2022).

29. Howard, D. M. *et al.* Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nat Neurosci* **22**, 343–352 (2019).

30. Kramarow, E. A. & Pastor, P. N. The health of male veterans and nonveterans aged 25-64: United States, 2007-2010. *NCHS Data Brief* 1–8 (2012).

31. Boersma, P., Cohen, R. A., Zelaya, C. E. & Moy, E. Multiple Chronic Conditions Among Veterans and Nonveterans: United States, 2015-2018. *Natl Health Stat Report* 1–13 (2021).

32. Hunter-Zinck, H. *et al.* Genotyping Array Design and Data Quality Control in the Million Veteran Program. *Am J Hum Genet* **106**, 535–548 (2020).

33. Fang, H. *et al.* Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-wide Association Studies. *Am J Hum Genet* **105**, 763–772 (2019).

34. Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature* **590**, 290–299 (2021).

35. Kowalski, M. H. *et al.* Use of >100,000 NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium whole genome sequences improves imputation quality and detection of rare variant associations in admixed African and Hispanic/Latino populations. *PLoS Genet* **15**, e1008500 (2019).

36. Williams, D. R. & Sternthal, M. Understanding racial-ethnic disparities in health: sociological contributions. *J Health Soc Behav* **51 Suppl**, S15-27 (2010).

37. Williams, D. R. & Mohammed, S. A. Discrimination and racial disparities in health: evidence and needed research. *J Behav Med* **32**, 20–47 (2009).

38. Denny, J. C. *et al.* Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. *Nat Biotechnol* **31**, 1102–1110 (2013).

39. Wu, P. *et al.* Mapping ICD-10 and ICD-10-CM codes to phecodes: Workflow development and initial evaluation. *J Med Internet Res* **21**, 1–13 (2019).

40. Wei, W. Q. *et al.* Combining billing codes, clinical notes, and medications from electronic health records provides superior phenotyping performance. *Journal of the American Medical Informatics Association* **23**, 20–27 (2016).

41. Wei, W.-Q. *et al.* Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. *PLoS One* **12**, e0175508 (2017).

42. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nat Commun* **10**, 1776 (2019).

43. Ding, Y. *et al.* Polygenic scoring accuracy varies across the genetic ancestry continuum in all human populations. *bioRxiv* 2022.09.28.509988 (2022) doi:10.1101/2022.09.28.509988.

44. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat Genet* **54**, 573–580 (2022).

45. Sohail, M. *et al.* Polygenic adaptation on height is overestimated due to uncorrected stratification in genome-wide association studies. *Elife* **8**, (2019).

46. Stammann, A., Heiss, F. & McFadden, D. Estimating Fixed Effects Logit Models with Large Panel Data. in *Beiträge zur Jahrestagung des Vereins für Socialpolitik 2016: Demographischer Wandel - Session: Microeconometrics, No. G01-V3* 1–40 (ZBW - Deutsche Zentralbibliothek für Wirtschaftswissenschaften, Leibniz-Informationszentrum Wirtschaft, 2016).

47. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series B (Methodological)* **57**, 289–300 (1995).

48. Barr, P. B. *et al.* Clinical, environmental, and genetic risk factors for substance use disorders: characterizing combined effects across multiple cohorts. *Mol Psychiatry* **27**, 4633–4641 (2022).

49. Gvion, Y., Levi-Belz, Y., Hadlaczky, G. & Apter, A. On the role of impulsivity and decision-making in suicidal behavior. *World J Psychiatry* **5**, 255 (2015).

50. Fletcher, J., Wu, Y., Li, T. & Lu, Q. Interpreting Polygenic Score Effects in Sibling Analysis. *bioRxiv* 2021.07.16.452740 (2021) doi:10.1101/2021.07.16.452740.

51. Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat Genet* **51**, 584–591 (2019).

52. Coleman, J. R. I. *et al.* Genome-wide gene-environment analyses of major depressive disorder and reported lifetime traumatic experiences in UK Biobank. *Mol Psychiatry* **25**, 1430–1446 (2020).

53. Choi, K. W. *et al.* Integrative analysis of genomic and exposomic influences on youth mental health. *J Child Psychol Psychiatry* **63**, 1196–1205 (2022).

54. Meffert, B. N. *et al.* US Veterans Who Do and Do Not Utilize Veterans Affairs Health Care Services: Demographic, Military, Medical, and Psychosocial Characteristics. *Prim Care Companion CNS Disord* **21**, 26992 (2019).

FIGURE CAPTIONS

Figure 1: PheWAS of Externalizing Polygenic Risk in MVP

Main PheWAS associations in veterans of the Ext PGS in primarily European ancestries (N = 406, 254). Panel A presents -log10 *p*-values for each of the 1,652 phecodes, grouped by phecode domain. Top associations are annotated within each grouping. Panel B presents the box plots for effect sizes (odds ratios, OR) by phecode grouping.

Figure 2: Multi-Ancestry Results for Externalizing Polygenic Risk in MVP

Selected associations and corresponding effect sizes (odds ratios, OR) of EXT PGS associations that replicated in either the African or Hispanic/Latin American ancestry groups.

Figure 3: Associations between EXT PGS and Selected Phecodes Accounting for DEP, SCZ, and SUI PGS

Main and Conditional PheWAS associations of the EXT PGS in veterans of primarily European ancestries (N = 406, 254). Panel A presents the phenome wide significant associations by PGS and their overlap. Panel B presents selected associations (and their corresponding effect sizes) between the marginal (EXT PGS only) and the conditional (EXT + DEP, SCZ, and SUI PGS) models.

Figure 4 Change in Effect Sizes for EXT PGS in Within-family Models

Change in effect sizes for significant associations in a sample of related veterans of primarily European ancestries (*N* = 12,127). Estimates represent the change between ordinary least squares models (with clustered standard errors) and family fixed effects models. All associations significant after correcting for a false discovery rate (FDR) of 5%.


A
Mental & Behavioral
Neurological
Sense Organs
Respiratory
Circulatory
Digestive
Endocrine & Metabolic
Pregnancy Complications
Genitourinary
Infectious Diseases
Hematopoietic
Musculoskeletal
Neoplasms
Dermatologic
Injuries & Poisonings
Symptoms NEC
Congenital Anomalies
Alcohol–related disorders
Anxiety disorders
Depression
Mood disorders
Substance addiction and disorders
Tobacco use disorder
Pain
Blindness and low vision
Chronic airway obstruction
Nonspecific chest pain
Other diseases of the teeth
Disorders of fluid, electrolyte, and acid–base balance
Acute renal failure
Viral hepatitis
Other anemias
Pain in joint
Cancer within the respiratory system
Superficial cellulitis and abscess
Contusion
Back pain
0
25
50
75
100
125
150
175
200
225
250
275
300
325
350
$-\log_{10}(P)$
B
respiratory
infectious diseases
injuries & poisonings
mental disorders
digestive
circulatory system
symptoms
musculoskeletal
hematopoietic
neoplasms
sense organs
neurological
genitourinary
dermatologic
congenital anomalies
endocrine/metabolic
pregnancy complications
0.9
1.1
1.3
1.5
Distribution of ORs


Personality disorders
Tobacco use disorder
Substance addiction and disorders
Alcohol−related disorders
Mood disorders
Viral hepatitis
Cancer within the respiratory system
Chronic airway obstruction
Chronic liver disease and cirrhosis
1.0
1.1
1.2
1.3
1.4
1.5
OR (95% CI)
HARE Grouping:
AFR
EUR
HIS


A
PGS overlap
208
202
116
77
35
35
29
15
13
12
10
9
8
6
4
SCZ
SUI
DEP
EXT
Associations per PGS
B
Substance addiction and disorders
Tobacco use disorder
Alcohol–related disorders
Suicidal ideation or attempt
Personality disorders
Conduct disorders
Mood disorders
Viral hepatitis
Other infectious and parasitic diseases
Human immunodeficiency virus [HIV] disease
Cancer within the respiratory system
Cancer of liver and intrahepatic bile duct
Cancer of larynx, pharynx, nasal cavities
Cancer of mouth
Atherosclerosis
Arterial embolism and thrombosis
Chronic airway obstruction
Respiratory failure, insufficiency, arrest
Empyema and pneumothorax
Pneumonia
Bronchitis
Poisoning by psychotropic agents
Fracture of ribs
Poisoning by agents primarily affecting blood constituents
Fracture of lower limb
Adverse drug events and drug allergies
OR (95% CI)
Analysis: Marginal Conditional


Viral hepatitis C
Chronic liver disease and cirrhosis
Neurological disorders
Cerebrovascular disease
Other dyspnea
Shortness of breath
Ischemic Heart Disease
Chronic airway obstruction
Tobacco use disorder
0.00
0.02
0.04
0.06
Change in EXT PGS Beta from OLS to Within−family
Model:
Within−family
OLS